Amorfix said that this finding supports the company’s platform technology for detecting aggregated misfolded proteins and expands the potential use of the assay to sporadic Creutzfeldt-Jakob disease (sCJD).
The company is seeking to acquire blood and spinal fluid from sCJD patients to assess whether the assay can be used for antemortem diagnosis of this disease.
Neil Cashman, chief scientific officer of Amorfix, said: “sCJD is the most common form of this brain wasting disease and has a profound impact on healthcare because of its potential for patient to patient transmission. An antemortem diagnostic test for sCJD would be an important step forward in managing the risk from this disease in healthcare settings.”